Software demonstrations-Commercial
S_1: Stephane Vellay Pipeline Pilot - Data Integration, Analysis, and Reporting Platform
S_2: Masoud Jamei Simcyp Simulator - a comprehensive platform and database for mechanistic modelling and simulation of drug absorption, tissue distribution, metabolism, transport and elimination in healthy and disease populations using in vitro knowledge
S_3: Sven Janssen SimBiology: A Graphical Environment for Population PK/PD
Software demonstrations-Non-commercial
S_10: Juergen Bulitta Development and Evaluation of a New Efficiency Tool (SADAPT-TRAN) for Model Creation, Debugging, Evaluation, and Automated Plotting using Parallelized S-ADAPT, Perl and R
S_11: Kajsa Harling Xpose and Perl speaks NONMEM (PsN)
S_12: Roger Jelliffe The MM-USCPACK software for nonparametric adaptive grid (NPAG) population PK/PD modeling, and the MM-USCPACK clinical software for individualized drug regimens.
S_13: Ron Keizer Piraña: Open source modeling environment for NONMEM
S_14: Marc Lavielle Analysing population PK/PD data with MONOLIX 3.2
S_15: Sebastian Ueckert PopED - An optimal experimental design software
Posters Wednesday Morning (group I)
Applications- Anti-infectives
I_1: Bambang Adiwijaya Applications of Discrete-Event Dynamic Simulation in HCV Treatment Dynamics
I_2: Jurgen Bulitta Mechanism-based Modelling of the Synergy of Colistin Combinations against Multidrug-Resistant Gram Negative Bacteria
I_4: Emmanuel Chigutsa Parallel first order and mixed order elimination of pyrazinamide in South African patients with tuberculosis
I_5: Isabelle Delattre Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin in critically ill septic patients
I_6: Oleg Demin Application of systems pharmacology modeling approach to optimize Interferon therapy of hepatitis C
I_7: Thomas Dorlo Optimal Dosing of Miltefosine in Children and Adults with Leishmaniasis
Applications- Biologicals/vaccines
I_8: Marion Dehez Bayesian framework applied to dose escalation studies for biologics
I_9: Amit Garg A Mechanism Based Population Pharmacokinetic-Pharmacodynamic Model for Epoetin Alfa and Darbepoetin Alfa in Chronic Kidney Disease Patients
I_10: Kenneth Luu A Mechanistic Approach to Predicting Human Pharmacokinetics of Monoclonal Antibodies from Preclinical Data: A Case Example
I_11: David Ternant Methotrexate influences neither pharmacokinetics nor concentration-effect relationship of infliximab in axial ankylosing spondylitis
I_12: Pawel Wiczling Pharmacokinetics and Pharmacodynamics of Anti-CD3 Monoclonal Antibody, Otelixizumab, in Subjects with Diabetes and Psoriasis
Applications- CNS
I_13: Neil Attkins Model based analysis of antagonist binding kinetics at CRF-1 receptors in vitro and in vivo
I_14: Marcus Björnsson Modeling of Pain Intensity Measured on a Visual Analogue Scale and Informative Dropout in a Dental Pain Model after Naproxcinod and Naproxen Administration
I_15: Jacob Brogren Transit Compartment Model Useful for Describing Absorption of Quetiapine XR and IR
I_16: Yu-Yuan Chiu Population Pharmacokinetics of Lurasidone in Healthy Subjects and Subjects with Schizophrenia
I_17: Vincenzo Luca Di Iorio Impact of Seizures and Efflux Mechanisms on the Biophase Kinetics and CNS Effects of Anticonvulsant Drugs
Applications- Oncology
I_18: Nicolas Azzopardi Pharmacokinetics and concentration-effect relationship of cetuximab in metastatic colorectal cancer
I_19: Anne Drescher Pharmacokinetic/Pharmacodynamic Modeling of Platinum-DNA-Adduct Formation in Leukocytes after Oxaliplatin Infusion
I_20: Jeroen Elassaiss-Schaap Allometric scaling in oncology disease progression from xenograft tumor growth to human non-small-cell lung cancer
I_21: Iñaki F. Trocóniz Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies using diflomotecan and indisulam
I_22: Ron Keizer Evaluation of clinical dosing of E7820 from preclinical and clinical data using a biomarker
Applications- Other topics
I_23: Claire Ambery Leveraging biomarker exposure-response in drug development
I_24: Jacqueline Anderson PK modelling of organophosphorus poisoning in humans
I_25: Massoud Boroujerdi Joint model for dropout in longitudinal trials in COPD patients
I_26: Karl Brendel Population pharmacokinetics-pharmacodynamics modeling of the QTc prolongation of Moxiflovoxacin and Levofloxacin in healthy volunteers: selection of the positive control in mandatory QT/QTc studies
I_27: Karl Brendel Using Modelling & Simulation techniques to optimise the design of a paediatric PK/PD study
I_28: Sophie Callies Integration of preclinical data to support the design of the first in-man study of LY2181308, a second generation antisense oligonucleotide.
I_29: Roosmarijn De Cock Predicting glomerular filtration rate using clearance of amikacin
I_30: Oleg Demin Jr Can systems modeling approach be used to understand complex PK-PD relationships? A case study of 5-lipoxygenase inhibition by zileuton
I_31: Pinky Dua SB-773812: Correlation between in-silico and in-vivo metabolism
Methodology- Model evaluation
I_32: Roberto Bizzotto Multinomial logistic functions in Markov-chain models for modeling sleep architecture: external validation and covariate analysis
I_33: Roberto Bizzotto PK-PD modeling of Wake after Sleep Onset time-course
I_34: Roberto Bizzotto Multinomial logistic functions in Markov-chain models for modeling sleep architecture: internal validation based on VPCs
I_35: Emmanuelle Comets Using simulations-based metrics to detect model misspecifications
I_36: Didier Concordet A new solution to deal with eta-shrinkage: the Weighted EBEs!
I_37: Paul Matthias Diderichsen A comparison of sequential and joint fitting of pain intensity and dropout hazard in acute pain studies
I_38: Paul Matthias Diderichsen Sufficiently high observation density justifies a sequential modeling approach of PKPD and dropout data
Methodology- Other topics
I_39: Margherita Bennetts Simulation Methodology for Quantitative Study Decision Making in a Dose Response Setting
I_40: Paul Baverel Informativeness of Internal and External Validation Techniques in Various Simulation Settings
I_41: Julie Bertrand Genetic effect on a complex parent-metabolite joint PK model developed with NONMEM and MONOLIX
I_42: Martin Boucher Imputation of missing variance data comparing Bayesian and Classical non- linear mixed effect modelling to enable a precision weighted meta-analysis.
I_43: Olivier Colomban Toxicogenomic dose-response model assessed by DNA chips on rats treated by flutamide
I_44: Paolo Denti Modelling pre-dose concentrations in steady-state data. The importance of accounting for between-occasion variability and poor adherence.
I_45: Gemma Dickinson Evaluation of a Method to Better Predict Human Absorption from Non-Clinical Data; Comparison of an in silico approach with population modelling of in vivo data
I_46: Aris Dokoumetzidis Fractional kinetics in multi-compartmental systems
Methodology- PBPK
I_47: Hesham Al-Sallami A semi-mechanistic model for estimating lean body weight in children
I_48: Marilee Andrew Physiologically Based Pharmacokinetic (PBPK) Modeling of Midazolam Disposition in Pregnant and Postpartum Women
I_49: Karina Claaßen Physiology-based Simulations of Amikacin Pharmacokinetics in Preterm Neonates
Late submissions
I_50: Gudrun Wuerthwein Population Pharmacokinetics of Liposomal Amphotericin B, Caspofungin and the Combination of Both in Allogeneic Hematopoietic Stem Cell Recipients
I_51: Peiming Ma Predicting Free Sclerostin from Free AMG 785 and Total Sclerostin
I_52: Leonid Gibiansky TMDD Model for Drugs that Bind Soluble and Membrane-Bound Targets: Can Quasi-Steady-State Approximation Estimate unobservable Membrane-Bound Target Occupancy?
I_53: Ronald Niebecker Impact of Different Body Size Descriptors on the Population Pharmacokinetics of a Monoclonal Antibody
Posters Wednesday Afternoon (group II)
Applications- Anti-infectives
II_1: Monika Frank Population Pharmacokinetic Model Building for Mothers and Newborns using Additional Information from a Different Nevirapine Dataset
II_2: Jeremie Guedj Design Evaluation and Optimization for models of Hepatitis C viral dynamics
II_3: Seong Bok Jang Population Pharmacokinetics of Amikacin in Korean Clinical Population
II_4: Siv Jonsson Population Pharmacokinetics of Ethambutol in South African Tuberculosis Patients
II_5: Dalia Khachman Population pharmacokinetic analysis of ciprofloxacin in intensive care unit adult patients
II_6: Holly Kimko Modeling & Simulation Exercise to Recommend Dosage Regimens for Patients with End-Stage Renal Disease Receiving Hemodialysis
Applications- CNS
II_7: Yuen Eunice A population pharmacokinetic/pharmacodynamic model for duloxetine in diabetic peripheral neuropathy, plus methods for handling missing data.
II_8: Martin Gnanamuthu Johnson Evaluation of a Mechanism-Based Pharmacokinetic-Pharmacodynamic Model for D2 Receptor Occupancy of Olanzapine in Rats
II_9: Gordon Graham Continuous time Markov modelling of relapse sojourns for relapse-remitting multiple sclerosis patients
II_10: Andrew Hooker Title: Modeling exposure-response relationships in the rat self-administration model
II_11: Matts Kågedal Estimation of occupancy and radioligand kinetics in the CNS from PET-data in the absence of a reference region.
II_12: Kristin Karlsson Clinical trial simulations using a stroke disease progression model
Applications- CVS
II_13: Anne Chain Not-in trial simulation: Prospective use of Not-In-Trial simulation
II_14: Carolyn Coulter Prediction of Torsades de Pointes from QT interval: analysis of a case series with amisulpride
II_15: Vincent Dubois Translation of drug-induced QTc prolongation in early drug development.
II_16: Anne-Kristina Frobel Physiologically-Based Pharmacokinetic (PBPK) Modelling of Bisoprolol in Adults and Children and External Model Validation in a Paediatric Clinical Trial
II_17: Florence Hourcade-Potelleret Preliminary Population PK-PD of Dalcetrapib: an Agent Targeting CETP to Raise HDL-C and Prevent Cardiovascular Morbidity and Mortality
II_18: Sergej Ramusovic An integrated whole-body physiology based pharmacokinetic/pharmacodynamic model of enalapril and the RAA-system
Applications- Oncology
II_19: Martin Fransson Pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model
II_20: Maria Garrido Population pharmacokinetic modelling of unbound and total plasma concentrations of oxaliplatin administered by hepatic arterial infusion to patients with liver-metastases.
II_21: Kimberley Jackson A Novel PKPD Model to Describe the Interaction of Drug Response of Combination Therapy: An Application in Preclinical Oncology.
II_22: Fredrik Jonsson A Longitudinal Tumor Growth Inhibition Model Based on Serum M-Protein Levels in Patients With Multiple Myeloma Treated by Dexamethasone
Applications- Other topics
II_23: Anne Dubois Model-based bioequivalence analysis of recombinant human growth hormone using the SAEM algorithm: liquid or lyophilized formulations of Omnitrope® versus original lyophilized Genotropin®
II_24: Anne Dubois Model-based bioequivalence analysis of pharmacokinetic crossover trial compared to standard non-compartmental analysis
II_25: Iñaki F. Trocóniz Population PK/PD model of the sedative effects of Flibanserin in healthy volunteers
II_26: Martin Fink Phase I trials: Model-based assessment to identify a clinical relevant change in heart rate
II_27: Nils Ove Hoem A population PK model of EPA and DHA after intake in phospholipid as well as in triglyceride form.
II_28: Ibrahim Ince Critical illness is a major determinant for midazolam and metabolite clearance in children
Methodology- Algorithms
II_29: Jeff Barrett A SAS-based Solution for NONMEM run management and post-processing
II_30: Mike Dunlavey Derivation of SAEM C-matrix in Phoenix
II_31: Marc Gastonguay Comparison of MCMC simulation results using NONMEM 7 or WinBUGS with the BUGSModelLibrary
II_32: Leonid Gibiansky Bias and Precision of Parameter Estimates: Comparison of Nonmem 7 Estimation Methods and PFIM 3.2 Predictions on the Example of Quasi-Steady-State Approximation of the Two-Target Target-Mediated Drug Disposition Model
II_33: Åsa Johansson New Estimation Methods in NONMEM 7: Evaluation of Bias and Precision
Methodology- Design
II_34:Caroline Bazzoli New features for population design evaluation and optimisation using PFIM3.2: illustration on warfarin pharmacokinetics - pharmacodynamics
II_35: Chao Chen Test Of Concept By Simulation: Comparing Response-Rate Findings Between Parallel And Titration Designs
II_36: Marylore Chenel Optimal design and QT-prolongation detection in oncology studies
II_37: Nicolas Frances Influence analysis explores heterogeneity in database before data processing by a parametric population method
II_38: Thu Thuy Nguyen Design evaluation and optimisation in crossover pharmacokinetic studies analyzed by nonlinear mixed effects models
Methodology- Model evaluation
II_39: Julie Grenier Population Pharmacokinetic and Pharmacodynamic Meta Analysis of Zenvia: Modeling of QT Prolongation
II_40: Julie Grenier Population Pharmacokinetic Meta Analysis: Inhibition by Quinidine of the First-Pass and Systemic Metabolism of Dextromethorphan to Dextrorphan
II_41: Chiara Piana The Influence Of Covariate Distribution On The Prediction And Extrapolation Of Pharmacokinetic Data In Children.
Methodology- Other topics
II_42: Charles Ernest Predictor Identification in Time-to-Event Analyses
II_43: Farkad Ezzet Analysis of Adverse Events using Literature Data: a Simulation Study
II_44: Farkad Ezzet Modeling Adverse Event rates of Opioids for the Treatment of Osteoarthritis Pain using Literature Data
II_45: Farkad Ezzet Bronchial Allergen Challenge in Asthma: A Model for Inhaled Corticosteroids (ICS) and Montelukast using Literature Summary Data
II_46: Roberto Gomeni Integrated approach to overcome a food effect in clinical studies: an example of how in vitro, in vivo and simulation tools can help in determining an appropriate strategy
II_47: Thaddeus Grasela Forensic Pharmacometrics: Part 1 - Data Assembly
II_48: Thaddeus Grasela Forensic Pharmacometrics: Part 2 - Deliverables for Regulatory Submission
II_49: Ivelina Gueorguieva Is pharmacokinetic variability in microdosing trials comparable to variability following therapeutic doses?
II_50: Michael Heathman Interactive Simulation and Visualization of Drug/Disease Models
II_51: Roger Jelliffe Pharmacogenomics and Individualized Dosage Regimens
II_52: Ron Keizer Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses
Posters Thursday Morning (group III)
Applications- Anti-infectives
III_1: Maria Kjellsson Penetration of Isoniazid, Rifampicin, Pyrazinamid and Moxifloxacin into Pulmonary TB Lesions in Rabbits
III_2: Michael Neely High-dose amoxicillin pharmacokinetics (PK) and pharmacodynamics (PD) in children
III_3: Thu Thuy Nguyen Population pharmacokinetic of linezolid in inpatients
III_4: Elisabet Nielsen Pharmacokinetic-Pharmacodynamic Modelling for Antibiotics: Static and Dynamic In Vitro Time-Kill Curve Experiments
Applications- CNS
III_5: Magdalena Kozielska Predictive performance of two PK-PD models of D2 receptor occupancy of the antipsychotics risperidone and paliperidone in rats
III_6: SeungHwan Lee A population analysis of Intravenous Dexmedetomidine in Korean
III_7: Gailing Li Towards Quantitative Prediction Of In Vivo Brain Penetration Using A Physiology Based CNS Disposition Model
III_8: Venkatesh Pilla Reddy Modeling and Simulation of Placebo Response and Dropout Patterns in Treatment of Schizophrenia
Applications- Oncology
III_9: Cornelia Landersdorfer Pharmacodynamic (PD) Modelling of Anti-Proliferative Effects of Tetraiodothyroacetic Acid (Tetrac) on Human Cancer Cells
III_10: Valerie Nock Leukopenia following high-dose chemotherapy with autologous stem cell retransfusion in patients with testicular cell cancer
Applications- Other topics
III_11: Elke Krekels Paracetamol pharmacokinetics in term and preterm neonates.
III_12: Yoon Jung Lee Model-based evaluation of DAS28 as a potential surrogate for ACR20 to establish the dose-response relationship for disease modifying anti-rheumatic drugs. A case study using tasocitinib (CP-690,550), an oral JAK inhibitor.
III_13: Ivan Matthews PKPD Modeling of Dose-Response & Time Course of B-Cell Depletion in Cynomolgus Monkeys
III_14: Jebabli Nadia Population Pharmacokinetics Of Vancomycin In Tunisian Patients
III_15: Jebabli Nadia Pharmacokinetic Modelling Of Methotrexate From Routine Clinical Data In Patients With Acute Lymphoblastic Leukemia
III_16: Jebabli Nadia Effect Of Clonidine On Bupivacaine Clearance In Tunisian Patients: Population Pharmacokinetic Investigation.
III_17: Chiara Piana Once Daily Pharmacokinetics Of Lamivudine In HIV-Infected Children
Methodology- Algorithms
III_18: Marc Lavielle The SAEM algorithm for Non-Linear Mixed Effects Models with Stochastic Differential Equations
III_19: Robert Leary Quasi-Monte Carlo EM Methods for NLME Analysis
III_20: Hafedh Marouani Nonparametric Approach using Gaussian Kernels Estimates Multivariate Probability Densities in Population Pharmacokinetics
III_21: Ines Paule Estimation of Individual Parameters of a Mixed–Effects Dose-Toxicity Model for Ordinal Data
III_22: Elodie Plan Nonlinear Mixed Effects Estimation Algorithms: A Performance Comparison for Continuous Pharmacodynamic Population Models
III_23: Sebastian Ueckert New Estimation Methods in NONMEM 7: Evaluation of Robustness and Runtimes
Methodology- Design
III_24: Sergei Leonov Optimization of sampling times for PK/PD models: approximation of elemental Fisher information matrix
III_25: Flora Musuamba-Tshinanu An optimal designed study for population pharmacokinetic modeling and Bayesian estimation of Mycophenolic acid and Tacrolimus early after renal transplantation
III_26: Flora Musuamba-Tshinanu Evaluation of disease covariates in chronic obstructive pulmonary disease (COPD).
III_27: Coen van Hasselt Application of a semi-physiological model describing time-varying pharmacokinetics to support optimal clinical study design
III_28: Joakim Nyberg Global, exact and fast group size optimization with corresponding efficiency translation in optimal design
Methodology- Model evaluation
III_29: Joakim Nyberg Investigations of the weighted residuals in NONMEM 7
III_30: Mary Lor Modeling and Simulation of Drug X and its Metabolite in Plasma and Urine
Methodology- Other topics
III_31: William Knebel A Strategy for Efficient Implementation of NONMEM 7 and the Intel Fortran Compiler in a Distributed Computing Environment
III_32: Brigitte Lacroix Simultaneous modeling of the three ACR improvement thresholds – 20, 50 and 70% - in rheumatoid arthritis patients treated with certolizumab pegol
III_33: Otilia Lillin-de Vries Population PK-PD modeling of thorough QT/QTc data allows for mechanistic understanding of observed QTc effects
III_34: Igor Locatelli The Development of a Link Model Consisting of in vitro Drug Release and Tablets Gastric Emptying Time: Application to Diclofenac Enteric Coated Tablets
III_35: Christophe Meille Probabilistic PK/PD model for ordered categorical toxicological data
III_36: Eugeniy Metelkin Application of pharmacokinetic-pharmacodynamic model to optimize dosing regime of antimicrobial drug Grammidin containing gramicidin S
III_37: Carmen Navarro Bioequivalence trials simulation to select the best analyte for drugs with two metabolic pathways
III_38: Ackaert Oliver A true Markov model for sleep disturbance
III_39: Henry Pertinez Bayesian POP-PK analysis of exposure data from a Phase IIb clinical trial
III_40: Leonid Gibiansky Target-Mediated Drug Disposition: New Derivation of the Michaelis-Menten Model, and Why It Is Often Sufficient for Description of Drugs with TMDD
Methodology- PBPK
III_41: Wojciech Krzyzanski An Interpretation of Transit Compartment Pharmacodynamic Models As Lifespan Based Indirect Response Models.
III_42: Jörg Lippert Clinical trial simulation with multiscale models: Integrating whole-body physiology, disease biology, and molecular reaction networks
III_43: Jörg Lippert Separating individual physiological variability from drug related properties using PBPK Modeling with PK-Sim® and MoBi® – Theophylline
III_44: Jörg Lippert Using relative gene expression measurements for PBPK modeling of pravastatin
III_45: Jörg Lippert Identifying cancer drug MoAs and cell-line properties using signaling cascade models and Bayesian analysis: From throw-away experiments to persistent information
III_46: Jörg Lippert Mechanistic analysis of fusion proteins: PBPK applied in an Albuferon case study
III_47: Jörg Lippert Influence of CYP1A1 induction by cigarette smoke on pharmacokinetics of erlotinib: a computer-based evaluation of smoke-induced CYP1A1 activity in different tissues
III_48: Jörg Lippert Simulation of the pharmacokinetics of flibanserin under itraconazole co-mediaction with an integrated physiologically-based pharmacokinetic model
III_49: Zinnia Parra Nonlinear Pharmacokinetic Model For Interleukin-12 Gene Therapy
III_50: Sabine Pilari Lumping of Physiologically Based Pharmacokinetic Models and a Mechanistic Derivation of Classical Compartmental Models
Posters Thursday Afternoon (group IV)
Applications- Anti-infectives
IV_1: Rada Savic Ciprofloxacin Integrated Plasma, Saliva and Sweat Population Pharmacokinetics and Emergence of Resistance in Human Commensal Bacteria
IV_2: Wynand Smythe A Semi-Mechanistic pharmacokinetic enzyme model for the characterisation of rifampicin pharmacokinetics in South African pulmonary tuberculosis infected adults
IV_3: Ami Fazlin Syed Mohamed Predictions of Dosing Schedules of Gentamicin in Neonates Based on a Pharmacokinetic/Pharmacodynamic Model Considering Adaptive Resistance
IV_4: Joel Tarning Population pharmacokinetics of antimalarial drugs in the treatment of pregnant women with uncomplicated malaria
IV_5: Toshihiro Wajima Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling for Integrase Inhibitors with a Simple Viral Dynamic Model
IV_6: Simbarashe Peter Zvada Effect of Four Different Meals Types on the Population Pharmacokinetics of single Dose Rifapentine in Healthy Male Volunteers
Applications- CNS
IV_7: Mahesh Samtani Switching to Paliperidone Palmitate[1,2] from Other Depot Antipsychotics: Guidance Based on Pharmacokinetic Simulations
IV_8: Monica Simeoni Clinical and Genetic factors affecting Alzheimer’s disease progression in subjects on stable acetylcholinesterase inhibitor therapy: a comparison between mechanistic and empirical disease progression modelling approaches
IV_9: Monica Simeoni Disease System Analysis: Evaluate the structural properties and the physiological implications of an indirect physiologic response model describing the degenerative progression of Alzheimer’s disease using a closed-form solution
IV_10: Armel Stockis Exposure-response modeling of daily seizure counts in focal epilepsy trials
IV_11: Mita Thapar Population Pharmacokinetics of Safinamide and its Effect on Disease Progression in Parkinson's Disease
IV_12: Pyry Välitalo Plasma and Cerebrospinal Fluid Pharmacokinetics of Naproxen in Children
IV_13: Marcel van den Broek Optimal dosing of lidocaine for seizure control in preterm and term neonates using population pharmacokinetic modelling and simulation
IV_14: Anders Viberg Using an Innovative Design in Behavioural Pharmacology Studies Saves Money and Animal Lives
IV_15: Stefano Zamuner The assessment of convulsion risk: a translational PK/PD modelling approach
Applications- Coagulation
IV_16: Anna-Karin Hamberg Internal and external evaluation of a K-PD model for warfarin using prediction corrected visual predictive check (PC-VPC)
IV_17: Hesham Al-Sallami A rationale for the routine monitoring of anti-activated factor X (anti-Xa) during enoxaparin treatment
Applications- Endocrine
IV_18: Anna Largajolli Assessment of the oral glucose minimal model by nonlinear mixed-effects approaches
IV_19: Elba Romero Development of a mechanistic-based pharmacodynamic model to describe the effect of a prolonged administration of a GnRH agonist on testosterone levels
Applications- Oncology
IV_20: Benjamin Ribba Combined analysis of tumor size data and histological biomarkers drives the development of a semi-mechanistic model of the effect of the antiangiogenic drug Sunitinib in mice
IV_21: Hauke Ruehs Homocysteine as biomarker in a semi-mechanistic PK/PD model of methotrexate
IV_22: Alexandre Sostelly Modelling the interaction between Irinotecan and efflux transporters inhibitors: A KPD tumour growth inhibition model including interaction components.
IV_23: Herbert Struemper Analysis of Biomarker Responses in Phase I Study of rhIL-18 in Combination with Rituximab in Non-Hodgkin’s Lymphoma to Support Phase 2 Dose Selection
IV_24: Hoai Thu Thai A mechanism-based model for the population pharmacokinetics of aflibercept in healthy subjects
IV_25: Mirjam Trame External Evaluation of a Population Pharmacokinetic Model for Dosing Busulfan in Children – Body Surface Area better than Body Weight
IV_26: Kellie Turner Cyclophosphamide, Methotrexate, and 5-Fluorouracil Population Pharmacokinetic Models with Pharmacogenetic Covariates
IV_27: Federico Verga Modeling of the metastatic variability in cancer disease.
IV_28: Christian Woloch Population Pharmacokinetics of 5FU and its Major Metabolite 5-FDHU in Colorectal Cancer Patients
IV_29: Alena Zhang Evaluating the Extent of Chemotherapeutic Contamination from Central Venous Catheters in Children with Cancer and Providing Guidance for Accurate Reporting of PK Parameters
Applications- Other topics
IV_30: Didier Renard A trial simulation example to support the design and model-based analysis of a new dose and regimen finding study
IV_31: Jan-Stefan van der Walt A population model describing the pharmacokinetics of iv esomeprazole in patients aged 0 to 17 years, inclusive
IV_32: Johan Wallin Internal and external validation with sparse, adaptive-design data for evaluating the predictive performance of a population pharmacokinetic model of tacrolimus
IV_33: Chenguang Wang Scaling clearance of propofol from preterm neonates to adults using an allometric model with a bodyweight-dependent maturational exponent
Methodology- Design
IV_34: Angelica Quartino Application of Optimal Design to Reduce the Sample Costs of a Dose-finding Study
IV_35: Sylvie Retout Bayesian modeling of a PK-PD relationship to support an adaptive dose-finding trial
IV_36: Amit Taneja Optimisation of experimental design for drug screening in behavioural models of pain.
IV_37: Donato Teutonico Development of a template for clinical trial simulations in COPD
IV_38: Sebastian Ueckert Comparison of Different Global Optimal Design Approximations
IV_39: Venkata Pavan Kumar Vajjah Generalisation of T-optimality for discriminating between competing models - an application to paracetamol overdose
Methodology- Model evaluation
IV_40: Italo Poggesi Modeling a time-dependent absorption constant: a trick and some considerations
IV_41: Stephan Schmidt Implication of differences in model parameterisation in osteoporosis
IV_42: Steven Xu A Casual Graphic Goodness-of-fit Assessment for Markov Pharmacodynamic Models
Methodology- Other topics
IV_43: Tarjinder Sahota Model-based safety thresholds for discrete adverse events
IV_44: Tarjinder Sahota The Chicken and the Egg in Interoccasion Variability
IV_45: Tobias Sing An R package for industrializing concentration-QT analysis
IV_46: Kuenhi Tsai Estimation Comparison of Pharmacokinetic Models Using MONOLIX, PKBUGS, and NONMEM
IV_47: Coen van Hasselt Implementation of an affordable computing cluster for pharmacometric analysis
IV_48: Paul Westwood A Pharmacokinetic Study of Ranitidine in a Paediatric Population
IV_49: Justin Wilkins A comparison of two model-based approaches to investigating covariate effects on the dose-exposure relationship in a Phase III context
Methodology- PBPK
IV_51: Cecile Gerard Influence of cyclosporin dosing schedule on receptor occupancy in bone marrow transplantation: analysis with a PBPK-PD model
IV_52: Julia Hövener Evaluation of a Physiologically-Based Pharmacokinetic (PBPK) Model for the Application of Low Dose Etoposide in Children
IV_53: Kirstin Thelen A novel physiological model to simulate gastrointestinal fluid dynamics, transit of luminal contents, absorption, and pre-systemic metabolism of orally administered drugs in humans
